Pfizer (PFE) Receives FDA Approval for XELJANZ as RA Treatment
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE)reports that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® (tofacitinib citrate) 5 mg twice ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
